[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022007947A - Derivado de amida de acido alifatico. - Google Patents

Derivado de amida de acido alifatico.

Info

Publication number
MX2022007947A
MX2022007947A MX2022007947A MX2022007947A MX2022007947A MX 2022007947 A MX2022007947 A MX 2022007947A MX 2022007947 A MX2022007947 A MX 2022007947A MX 2022007947 A MX2022007947 A MX 2022007947A MX 2022007947 A MX2022007947 A MX 2022007947A
Authority
MX
Mexico
Prior art keywords
sup
sub
acid amide
aliphatic acid
amide derivative
Prior art date
Application number
MX2022007947A
Other languages
English (en)
Inventor
Andrew Simon Bell
Yoshinori Aihara
Jeremy Besnard
Yuki Fujii
Masayuki Sakuma
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Publication of MX2022007947A publication Critical patent/MX2022007947A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un compuesto representado por la fórmula (1) (ver Fórmula), teniendo el compuesto actividad antagonista contra los receptores de serotonina 5-HT2A y los receptores de serotonina 5-HT7; o una sal farmacéuticamente aceptable del compuesto; (en la fórmula, Z es un átomo de nitrógeno y similares; Y es carbonilo y similares; m y n son 1 y similares; R1a a R1d, R2a a R2d, y R4a a R4d son átomo de hidrógeno y similares; R3 es alquilo y similares; y Q es un grupo bicíclico específico).
MX2022007947A 2019-12-24 2020-12-23 Derivado de amida de acido alifatico. MX2022007947A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019232927 2019-12-24
PCT/JP2020/048117 WO2021132311A1 (ja) 2019-12-24 2020-12-23 脂肪族酸アミド誘導体

Publications (1)

Publication Number Publication Date
MX2022007947A true MX2022007947A (es) 2022-07-27

Family

ID=76574184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007947A MX2022007947A (es) 2019-12-24 2020-12-23 Derivado de amida de acido alifatico.

Country Status (11)

Country Link
US (2) US20220213079A1 (es)
EP (1) EP4082616A4 (es)
JP (1) JPWO2021132311A1 (es)
KR (1) KR20220120625A (es)
CN (1) CN114981264B (es)
AU (1) AU2020413284A1 (es)
BR (1) BR112022011844A2 (es)
CA (1) CA3161806A1 (es)
MX (1) MX2022007947A (es)
TW (1) TW202136235A (es)
WO (1) WO2021132311A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880930A (en) * 1987-11-30 1989-11-14 New James S Psychotropic acyclic amide derivatives
PT732332E (pt) 1995-03-17 2002-06-28 Aventis Pharma Inc Benzotienilpiperazinas substituidas sua utilizacao como medicamentos e processos para a sua preparacao
US5880121A (en) * 1996-01-05 1999-03-09 Hoechst Marion Roussel Inc. 4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof
EP1361875A2 (en) * 2001-02-16 2003-11-19 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
FR2827287B1 (fr) * 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR0316108A (pt) * 2002-11-08 2005-09-27 Warner Lambert Co Derivados de fenilalquil e piridilalquil piperazina e composição farmacêutica compreendendo os mesmos
WO2006116614A1 (en) * 2005-04-26 2006-11-02 Hypnion, Inc. Benzisoxazole piperidine compounds and methods of use thereof
PL392436A1 (pl) * 2010-09-17 2012-03-26 Adamed Spółka Z Ograniczoną Odpowiedzialnością Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
EP2924033B1 (en) * 2012-11-26 2019-02-27 Shenyang Haiwang Biotechnology Co., Ltd Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives

Also Published As

Publication number Publication date
AU2020413284A1 (en) 2022-08-18
JPWO2021132311A1 (es) 2021-07-01
US11339151B2 (en) 2022-05-24
EP4082616A1 (en) 2022-11-02
CN114981264A (zh) 2022-08-30
KR20220120625A (ko) 2022-08-30
BR112022011844A2 (pt) 2022-08-30
TW202136235A (zh) 2021-10-01
CA3161806A1 (en) 2021-07-01
CN114981264B (zh) 2024-07-26
EP4082616A4 (en) 2024-01-03
WO2021132311A1 (ja) 2021-07-01
US20220213079A1 (en) 2022-07-07
US20220073506A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
MX2019012336A (es) Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.
RU2012126129A (ru) Производное индола и его фармацевтическое применение
EA200701583A1 (ru) Гетероциклические тетрациклические производные гидрофурана в качестве ингибиторов 5нт2 в терапии расстройств цнс
MX2012001313A (es) Compuesto espirociclicos que contienen nitrogeno y su uso medicinal.
EA200701640A1 (ru) Новые соединения с терапевтическим эффектом
EA200400981A1 (ru) Новые гетероциклические соединения, активные в качестве ингибиторов бета-лактамаз
MY141559A (en) Triazole derivatives as tachykinin receptor antagonists
MX2009004910A (es) Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo.
TW200745058A (en) MMP-13 selective inhibitors
UA108510C2 (en) Cyclopropane compound
AR046085A1 (es) Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico
PH12017501655B1 (en) Morphinan derivative
ZA202108263B (en) Imidazolonylquinoline compounds and therapeutic uses thereof
MXPA04002570A (es) Compuestos que inhiben la liberacion de citocinas inflamatorias.
MX2024003130A (es) Amida 1,4-dihidro-1,6-naftiridina sustituida y uso de la misma.
SG11201810725WA (en) Novel β-lactamase inhibitors
MX2022007947A (es) Derivado de amida de acido alifatico.
IN2013MN00506A (es)
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
WO2004005256A3 (en) Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors
MX2023003245A (es) Derivados de amina novedosos.
MXPA05012096A (es) Derivados de amina ciclica, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
WO2022206730A8 (zh) 嘧啶并吡嗪酮化合物及其用途
MX2023013803A (es) Sal farmaceuticamente aceptable del derivado de pirazoloheteroarilo y forma cristalina del mismo.